Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Triple Negative Breast Neoplasms 1

Interventions

Specimen Handling 449Magnetic Resonance Spectroscopy 344pembrolizumab 296Biopsy 247Carboplatin 235Cisplatin 198Cyclophosphamide 190Paclitaxel 167Nivolumab 158Gemcitabine 154Bevacizumab 125Radiotherapy 122Dexamethasone 115fludarabine 102Pemetrexed 102Fluorouracil 96Doxorubicin 92venetoclax 91durvalumab 91Radiation 91Docetaxel 91atezolizumab 90Oxaliplatin 89Rituximab 88Leucovorin 82Capecitabine 78Prednisone 77Lenalidomide 71Etoposide 69X-Rays 67

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Ivermectin × 30 days × Clear all
NCT05318469 2026-05-06

Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer

Cedars-Sinai Medical Center

Phase 1/2 Recruiting
34 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡